Trifork Group (TRIFOR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
27 Feb, 2026Executive summary
Achieved strong product-led transition with 27% revenue growth in Products and high demand for managed sovereign data solutions, especially in healthcare and public sector contracts.
Revenue for 2025 reached EUR 220.9M, up 7.3% year-over-year, with organic growth at 7.2%.
Adjusted EBITDA for 2025 was EUR 33.3M, a 35% increase from the prior year, with margin rising to 15.1%.
Cost control initiatives led to a 3.5 percentage point margin recovery, strong cash conversion, and a robust balance sheet.
Free cash flow improved to EUR 27.3M for 2025, up from EUR 11.4M in 2024.
Financial highlights
Q4 2025: 5% total revenue growth, 9% organic growth, and 18.1% adjusted EBITDA margin (+3.5 p.p. YoY).
FY 2025: 7% total and organic revenue growth, 13.6%–15.1% group adjusted EBITDA margin, and 23%–35% YoY EBITDA increase.
Operating cash conversion at 98% and net debt/adj. EBITDA at 0.6x (down from 1.3x in 9M 2025).
EBIT for 2025 was EUR 16.8M, with an EBIT margin of 7.6%.
Free cash flow conversion reached 97.9% for 2025.
Outlook and guidance
2026 guidance: Group revenue EUR 230–240m (6.7–11.3% organic growth YoY), group adj. EBITDA EUR 35–40m (14.6–17.4% margin, 16.2–32.8% growth YoY).
Management notes seasonality in both Products and Services, with higher revenue and profit in the first half of the year.
Continued focus on product growth, cost control, and capital reallocation to core business and buybacks.
Latest events from Trifork Group
- Record 2025 revenue, strong product growth, margin gains, and robust 2026 outlook.TRIFOR
Q4 202527 Feb 2026 - Revenue and margins fell, but public sector momentum and Labs gains support future outlook.TRIFOR
Q2 202423 Jan 2026 - Product-driven growth, innovation in AI and digital health, and strong 2025 financial targets.TRIFOR
Danske Bank Winter Seminar presentation19 Jan 2026 - Revenue and margins fell in 2024, triggering cost cuts and growth in US and public sector Denmark.TRIFOR
Q3 202417 Jan 2026 - Q2 2025 revenue up 5.1%, with product focus and digital health wins fueling future growth.TRIFOR
Investor presentation16 Jan 2026 - Product-driven growth, innovation in AI, and strong 2025 financial targets define the outlook.TRIFOR
Investor presentation16 Jan 2026 - Product-led transformation, robust 2025 outlook, and strong Labs investment performance.TRIFOR
SEB Nordic Seminar presentation16 Jan 2026 - Labs portfolio value reaches EUR 84m, with strong exits and high-growth companies driving returns.TRIFOR
Investor update13 Jan 2026 - Record Q4, flat full-year, 2025 targets growth via cost savings and US/product focus.TRIFOR
Q4 20242 Dec 2025